Cytokinetics, Incorporated Cytokinetics, Incorporated

Cytokinetics, Incorporated

CYTK

Ранг среди акций #2258
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Цена акции
$64.11
Рыночная капитализация
$8.91B
Изменение (1 день)
2.34%
Изменение (1 год)
8.03%
Страна
US
Торговля Cytokinetics, Incorporated (CYTK)

Категория

Healthcare
История дроблений акций Cytokinetics, Incorporated (CYTK)
Акции Cytokinetics, Incorporated (символ: CYTK) прошли через 1 дроблений.
Последнее дробление произошло Jun 25, 2013.
Одна акция CYTK, купленная до Jun 25, 2013, сейчас соответствует 0.16666666666667 акциям CYTK.
Список дроблений акций
Год Дробление Коэффициент Суммарный коэффициент
2013-06-25 1:6 x0.16666666666667 x0.16666666666667
Дробления акций аналогичных компаний или конкурентов
Компания Количество дроблений акций Суммарный коэффициент Страна
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL